Answers are grounded in this paper and cite their sources.
Although diverse acylation modification (DAM) drives malignant progression and therapeutic resistance in ovarian cancer (OV), its underlying mechanisms remain poorly understood. This study comprehensively analyzed DAM in OV by integrating multi-omics datasets, including 12 transcriptome datasets and spatial transcriptome datasets. Based on the expression characteristics of DAM, we developed a DAM.score prognostic feature. The DAM.score that was developed exhibited exceptional predictive abilities in anticipating outcomes for OV and surpassed the currently employed prognostic indicators related to OV. In addition, the predictive strength of DAM.score was not limited to OV; it was corroborated across a variety of cancer types, illustrating its extensive relevance in assessing responses to immunotherapy. Biologically, the investigation uncovered notable correlations between DAM.score and different immunological parameters. Specifically, higher DAM.score levels corresponded with enhanced immune responses, which were associated with traits typically linked to immunologically active tumors-those capable of generating a vigorous immune reaction. Detailed spatial transcriptomics analyses indicated that a heightened DAM.score was connected to an increase in cellular malignancy. TIAM1 has been identified as a critical molecular component within the overarching framework of OV, and increased levels of TIAM1 expression were linked to worse clinical outcomes in OV. From a mechanistic perspective, TIAM1 knockout activates cytotoxic CD8⁺ T cells while suppressing immunosuppressive cell populations. This finding highlights the potential of targeting TIAM1 for therapeutic strategies, as its absence can activate immune mechanisms that may counteract tumor growth and improve patient prognosis.
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: